Renowned UCLA Molecular Biologist Richard A. Gatti, M.D. Named to NeoStem Medical Advisory Board

AGOURA HILLS, Calif.--()--June 21, 2004--NeoStem (www.neostem.com), a groundbreaking company committed to pioneering adult stem cell therapeutics, announced today that Richard A. Gatti, M.D., Co-Director of the Molecular Pathology Laboratory at UCLA, has been named to the firm's Medical Advisory Board.

Dr. Gatti is currently a distinguished professor of Pathology and Laboratory Medicine. He is a world-renowned molecular geneticist and immunologist and a pioneer in transplantation medicine. Dr. Gatti specializes in Ataxia Telangiectasia (A-T), Friedreich's Ataxia (FA) and cell sensitivity to ionizing radiation. He also serves as director of the UCLA Center for A-T Research.

After receiving his B.A. from Columbia College and his M.D. at St. Louis University School of Medicine, he trained in immunology with Dr. Robert Good at the University of Minnesota, and tumor immunology with Dr. Georg Klein of Karolinska Institute, Stockholm.

"NeoStem is making huge strides in advancing the use of one's own adult stem cells as a treatment option for those who develop heart disease, certain types of cancer and other critical health problems," said Dr. Gatti. "I'm honored to be part of NeoStem's Medical Advisory Board, and look forward to working with my peers to help make autologous stem cell therapy a new standard of care where appropriate."

"We're delighted to welcome Dr. Gatti to our Medical Advisory Board," said Denis Rodgerson, Ph.D., CEO, NeoStem. "His expertise in transplantation medicine will be an asset as we work to further develop adult stem cell therapeutics and continue the process of educating the public about the benefits of storing one's own stem cells for possible future use to fight various life-threatening diseases. As we reach out to all of the various affected populations, Dr. Gatti will be a key part of our team."

NeoStem's mission is to be the leading provider of adult stem cell medical services -- a powerful alternative to embryonic stem cell research. Emerging therapies involving one's own adult stem cells are expected to grow rapidly as regenerative medicine revolutionizes treatment options in the 21st Century. According to the National Institutes of Health, stem-cell research "has the potential to revolutionize the practice of medicine and improve the quality and length of life." The American Heart Association recognized adult stem cell transplantation for cardiac patients as among the "Top 10 Lifesaving Advances of 2003."

Dr. Gatti's addition to the NeoStem Medical Advisory Board follows the recent appointment of Nelson Chao, M.D., MBA, Professor of Medicine and Immunology, and Chief, Division of Cellular Therapy/BMT at Duke University.

About NeoStem

Based in Agoura Hills, Calif., NeoStem Inc. (www.neostem.com) is pioneering the pre-disease collection, processing and storage of adult stem cells for future medical treatments. NeoStem is engaged in autologous stem cell collection for therapy, which does not involve embryonic or fetal stem cells in any way. NeoStem was founded by former executives and founders of StemCyte, Inc., the world's second largest umbilical cord stem cell bank. In addition to other proprietary intellectual properties in the field of stem cell therapeutics, cellular biology and laboratory medicine, the company has developed and filed numerous patents on the processing techniques and therapeutic applications of adult stem cells for future health care needs.

Contacts

Edge Communications, Inc.
Ken Greenberg, 818-719-9292
ken@edgepress.com

Contacts

Edge Communications, Inc.
Ken Greenberg, 818-719-9292
ken@edgepress.com